lacosamide / Generic mfg.  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lacosamide / Generic mfg.
NCT01390909: Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database

Completed
N/A
12386
US
Anti-epileptic drug (AED), Mysoline® is a registered trademark of Valeant Pharmaceuticals, Neurotin® is registered trademark of Pfizer, Inc, Vimpat® is a registered trademark of UCB Pharma, Tegretol® is a registered trademark of Novartis Pharmaceuticals, Trileptal® is a registered trademark of Novartis Pharmaceuticals, Sabril® is a registered trademark of Lundbeck Inc, Felbatol® is a registered trademark of MedPointe, Topamax® is a registered trademark of Ortho-McNeill-Janssen Pharmaceuticals, Depakote® is a registered trademark of Abbott Laboratories, Zonegran® is a registered trademark of Dainippon Pharmaceutical C. Ltd., Gabatril® is a registered trademark of Cephalon, Keppra® is registered trademark of UCB Pharma, Zarontin® is a registered trademark of Pfizer, Lamictal® is a registered trademark of GlaxoSmithKline, Luminal® is a registered trademark of Abbott Laboratories, Dilantin® is a registered trademark of Pfizer, Lyrica is registered trademark of Pfizer
GlaxoSmithKline
Epilepsy
01/11
01/11
NCT01587339: Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy

Completed
N/A
6498
Europe
retigabine/ezogabine, Trobalt (R); Potiga (R), lacosamide, Vimpat, zonisamide, Zonegran, pregabalin, Lyrica, eslicarbazepine, Zebinix
GlaxoSmithKline
Epilepsy
03/11
07/11
PASS, NCT00771927: Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures

Completed
N/A
1005
Europe
Lacosamide, Vimpat®
UCB Pharma
Epilepsies, Partial
03/12
03/12
NCT01382017: Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study

Completed
N/A
18
Europe
Lacosamide, Placebo, Carbamazepine
University of Kiel, UCB Pharma
Healthy Male Volunteers
08/12
08/12
VITOBA, NCT01098162: Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug

Completed
N/A
576
Europe
UCB Pharma GmbH
Epilepsies, Partial
07/13
07/13
NCT01296880: Effects of Adjunctive Lacosamide on Mood States and Quality of Life (QOL) in Patients With Epilepsy

Completed
N/A
60
US
State University of New York - Downstate Medical Center, UCB Pharma
Epilepsy
07/14
07/14
VICTOS, NCT01673282: Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy

Completed
N/A
315
Europe
Lacosamide, Vimpat, LCM
UCB Pharma GmbH
Focal Epilepsy With and Without Secondary Generalization
07/15
07/15
VIBES, NCT02276053: Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors

Completed
N/A
93
Europe
UCB BIOSCIENCES GmbH, PRA Health Sciences
Brain Tumor Related Epilepsy (BTRE)
12/17
12/17
NCT03559673: Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures

No Longer Available
N/A
NA
Lacosamide, Vimpat
UCB Biopharma S.P.R.L.
Epilepsies, Partial
 
 

Download Options